Amylyx Pharmaceuticals (AMLX) Liabilities and Shareholders Equity (2021 - 2026)

Amylyx Pharmaceuticals has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $264.6 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 35.95% year-over-year to $264.6 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 46.0% increase from a year earlier, with the FY2025 full-year figure at $332.6 million, up 71.79% from the prior year.
• Liabilities and Shareholders Equity was $264.6 million for Q2 2026 at Amylyx Pharmaceuticals, down from $293.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $517.5 million in Q4 2023, with the low at $181.4 million in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $321.1 million, with a median of $312.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 270.64% in 2022, then tumbled 62.58% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $391.5 million in 2022, then surged by 32.19% to $517.5 million in 2023, then sank by 62.58% to $193.6 million in 2024, then jumped by 71.79% to $332.6 million in 2025, then fell by 20.47% to $264.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $264.6 million (Q2 2026), $293.6 million (Q1 2026), and $332.6 million (Q4 2025), per Business Quant data.